AmerZeidanMDMBBS, MHS

Oncology • New Haven, CT

Hematologic Oncology

Assistant Professor of medicine, Yale university

Join to view full profile

Dr. Zeidan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zeidan's full profile

Already have an account?

Office
20 York St
New Haven, CT 06510
Phone+1 203-688-4242

Fax+1 203-688-5013

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester General HospitalResidency, Internal Medicine

Certifications & Licensure

CT State Medical License 2014 - 2025
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014
American Board of Internal Medicine Hematology

Clinical Trials

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
Active, not recruiting
Phase 1
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
Recruiting
Phase 2
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Terminated
Phase 2
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Start of enrollment: 2021 Feb 16
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

93 citations
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24
38 citations
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller
Clinical Cancer Research. 2020-09-30
27 citations
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
Olumide B. Gbolahan, Amer M. Zeidan, Maximilian Stahl, Mohammad Abu Zaid, Sherif S. Farag
International Journal of Molecular Sciences. 2017-07-31

Lectures

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Is AML Harder to Treat After Relapse?March 6th, 2020
Trovagene (TROV) Stock: Providing New Cancer Treatment Options with OnvansertibDecember 11th, 2018
$Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AML$
Breaking News: Trovagene Reports New Data from Phase 1b/2 Study of Onvansertib Demonstrates Response to Treatment in Relapsed/Refractory AMLDecember 3rd, 2018
Join now to see all